Video

Dr. Jeffrey Trent on the Melanoma Dream Team

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute (TGen), discusses the Stand Up to Cancer (SU2C)-Melanoma Research Alliance (MRA) Dream Team.

The SU2C-MRA Dream Team focuses on investigating the utility of personalized targeted therapies and therapy identification in specific subgroups of patients with melanoma, such as BRAF wild-type. At TGen, researchers primarily focus on genomic information, looking at both hereditary information and genetic changes in cancer cells, to examine differences and impact clinical decision-making, Trent explains.

The SU2C-MRA Dream Team is three years into developing approaches, infrastructure, technologies, and reporting associated with FDA regulatory approvals. Thus far, Dream Team researchers have examined approximately seven patients out of more than 100 enrolled in the trial, Trent says.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP